- Prepping for Colonoscopy? An Expert Offers Tips to Make Things Easier
- Online Yoga Classes Can Ease Lower Back Pain
- Ozempic, Wegovy Could Help Ease Knee Arthritis Pain
- Weight-Loss Surgery for Teens Brings Lasting Benefit
- Sleep Apnea Could Raise Dementia Risk, Especially for Women
- Quitting Smoking After Cancer Diagnosis Boosts Survival by Up to 26%
- When Is It OK to Undergo Routine Surgery After a Heart Attack?
- Money, Education Helps Determine Your Odds for Dementia
- Scientists Successfully Reverse Liver Fibrosis in Mice
- No Evidence Adults With Autism Are More Vulnerable to Criminals, Study Finds
Raplixa Approved to Control Surgical Bleeding
Raplixa (human fibrin sealant) has been approved by the U.S. Food and Drug Administration to help control bleeding during surgery, the agency said in a news release.
Raplixa’s use is sanctioned when standard surgical techniques — including sutures — are “ineffective or impractical,” the FDA said. The spray-dried product is dissolved in the blood and triggers a reaction that promotes clotting to help stop bleeding.
The product contains fibrinogen and thrombin, two proteins derived from human plasma. Its manufacturing process includes purification designed to render blood-borne viruses inactive, the agency said.
Raplixa, designed to be used with an absorbable gelatin sponge, was clinically evaluated among more than 700 people over 11 months. The most common side effects included surgical pain, nausea, constipation, fever and lower blood pressure.
The product is manufactured by ProFibrix BV, a unit of The Medicines Company, based in Parsippany, N.J.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.